Abstract
A comprehensive examination of 6 major CNS therapy areas: neurodegenerative
disorders, multiple sclerosis, ADHD, depression, sleep disorders and
schizophrenia. The report includes unique market share and sales forecasts by
product to 2012, as well as detailed competitor analysis of current and
upcoming products.
Understand the prospects for this US$67.8 billion market!
- Unique market share and sales forecasts by product to 2012
- A comprehensive examination of 6 major CNS therapy areas
- Detailed competitor analysis of current and upcoming products
Among the key developments addressed in the new 750-page November 2006 edition:
Neurodegenerative Disorders
- What are the leading Alzheimer' s and Parkinson' s disease brands?
- What disease-modifying agents are emerging?
- How are companies managing the patent exposure within their
neurodegenerative portfolios?
Multiple Sclerosis
- How is Tysabri (Elan) performing following its temporary suspension?
- What is the latest clinical data on Mylinax (Serono/IVAX) and Neurelan
(Elan/Acorda)?
- What other products are in the pipeline?
Attention Deficit Hyperactivity Disorder (ADHD)
- What products are in Phase II/III and when will they reach the market?
- How is the launch of Shire' s MethyPatch going?
- To what degree will the approval of NRP104 (Shire/New River) change the
market dynamics?
Depression
- What impact have generics had on market dynamics?
- How have safety concerns influenced prescribing habits?
- What Phase IV data has driven sales?
Sleep Disorders
- Will Neurocrine' s indiplon reach the market?
- How does gaboxadol (Merck & Co/ Lundbeck) compare to its peers?
- What is sanofi-aventis' pipeline looking like?
Schizophrenia - new in this edition!
- How has the safety of atypical antipsychotics affected the market?
- Who is the market leader and why?
- What pipeline products are in development and how do they compare with the
competition?
View Cart
